July 23, 2025

Figure 2 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Authors

THTae HataKyoto Prefectural University TYTadaaki YamadaKyoto Prefectural University of Medicine YGYasuhiro GotôFujita Health University

Discussion

Member takes

Implication

Observational study shows that liver metastases affect overall survival in non-small cell lung cancer, suggesting implications for treatment with immune checkpoint inhibitors.

Key Points

Chemoimmunotherapy may improve overall survival in patients with low PD-L1 expressing non-small cell lung cancer.
Kaplan–Meier curves reveal distinct overall survival and progression-free survival rates based on liver metastases status.
Patients with a history of ATB therapy were analyzed alongside liver metastases to determine their impact on outcomes.
These findings highlight the importance of considering liver metastases when treating non-small cell lung cancer with immune therapies.

Cite This Study

Hata et al. (2025) studied this question.

synapsesocial.com/papers/689a0621e6551bb0af8cdb9a https://doi.org/10.1158/2767-9764.29624066

View Full Paper

Ask AI

Bookmark

Implication

Observational study shows that liver metastases affect overall survival in non-small cell lung cancer, suggesting implications for treatment with immune checkpoint inhibitors.

Figure 2 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Figure 2 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider